Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immediate-early protein 1 (IE1) is a major regulatory protein of human cytomegalovirus, essential for the initiation of the viral replication cycle and latent/lytic gene expression programs. The "exon 4" segment of IE1 is a highly immunogenic region that has been used in vaccine development due to its strong capacity to elicit HCMV-specific T cell responses. IE1 antagonizes host cell antiviral processes (notably PML nuclear body-mediated restriction), contributes to evasion of intrinsic immunity by binding and modifying cellular proteins, and plays a role in epigenetic regulation and establishment of viral latency[5][3][8][1]. “IE1-exon4” is not a full-length gene or protein, but designates a region within the main IE1 protein; its primary importance is as an epitope recognized by the immune system and as a tool in research for CMV vaccine antigen design.
When used in vaccine research, presented IE1-exon4-derived antigens elicit T cell-mediated immune responses that recognize and eliminate CMV-infected cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immediate-early protein 1 (exon 4) (IE1-exon4).